Bli medlem
Bli medlem

Du är här

2016-05-20

DBV Technologies: DBV Technologies to Attend Upcoming Investor Conferences

----------------------------------
| Press Release |
| |
|Montrouge, France, May 20, 2016 |
----------------------------------

DBV Technologies to Attend Upcoming Investor Conferences

DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that members of its management team will present and host investor meetings
at the following investor events:

* Susanna Mesa, Senior Vice President, Strategy, will present at the UBS
Global Healthcare Conference in New York, NY, on Monday, May 23, 2016 at
3:30 pm ET
* Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays
West Coast Biopharma Conference in Calistoga, CA, on Wednesday, June 1,
2016 at 1:30 pm PT.
* Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice
President, Strategy, will present at the Jefferies 2016 Healthcare
Conference in New York, NY, on Tuesday, June 7, 2016, at 3:30 pm ET.

A live webcast of the Jefferies 2016 Healthcare Conference will be available
on the Investor Relations section of the Company's
website:http://www.dbv-technologies.com/en/investor-relations. A replay of
the presentation will also be available on DBV's website within 48 hours
after the event.

About DBV Technologies

DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With this new
class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for
whom there are no approved treatments. DBV's food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV is also pursuing a human proof concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis,
and exploring potential applications of its platform in vaccines and other
immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York,
NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our
website:www.dbv-technologies.com

---------------------------------------------------
| DBV Technologies Contact |
| Susanna Mesa |
| |
| |
|Senior Vice President, Strategy |
|+1 212-271-0861 |
|susanna.mesa@dbv-technologies.com |
| Media Contacts |
| Erinn White, Centron PR |
| |
|+1 646-722-8822 |
|ewhite@centronpr.com |
| |
| |
| |
| |
|Marion Janic, Rooney&Associates |
| |
|+1 212-223-4017 |
|mjanic@rooneyco.com |
| Media Contacts, Europe |
| |
|Caroline Carmagnol, Alize RP - Relation Presse |
| |
|+33 (0)6 64 18 99 59 |
|caroline@alizerp.com |
| |
---------------------------------------------------
PDF Version
http://hugin.info/156437/R/2013661/746310.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#2013661

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.